Yahoo Finance

ProPhase Labs’ Linebacker-1 Cancer Therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to ...

Garden City, NY, May 03, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a next-generation biotech, genomics and diagnostics company, today provided an update regarding its ...
Drug Store News

Matrixx ups takeover bid of ProPhase to $1.60 per share

SKILLMAN, N.J. — Matrixx Initiatives on Tuesday announced its second overture to ProPhase Labs with an increased acquisition offer of $1.60 per share. The revised offer represents a premium of 51.7% ...
Seeking Alpha

ProPhase Labs: Lots Of Moving Pieces

Medical diagnostic and testing concern ProPhase Labs, Inc. gets put in the spotlight today. ProPhase Labs, Inc. has seen huge revenue growth from Covid testing but is rapidly diversifying into other ...
Yahoo Finance

ProPhase Labs Closes Acquisition of BE-Smart Esophageal Pre-Cancer Diagnostic Screening Test

GARDEN CITY, NY, Jan. 05, 2023 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase”), a growth oriented and diversified diagnostics, genomics and biotech company, today announced it has ...

ProPhase Labs Announces Publication of BE-Smart Esophageal Cancer Study in the Official Journal of the American College of Gastroenterology

Peer-Reviewed Study Conducted in Collaboration with Mayo Clinic Demonstrates 100% Sensitivity and Strong Predictive Power for Esophageal Cancer ...
MarketWatch

Matrixx ups bid for ProPhase to $1.60 a share

NEW YORK (MarketWatch) -- Matrixx Initiatives Inc. on Tuesday increased its buyout offer for ProPhase Labs Inc. by 14% to $1.60 a share in cash from its earlier offer of $1.40 a share. Shares of ...